July 2nd 2025
A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.
Current Challenges With MDD Treatment Options
February 2nd 2023Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.